美国MedImmune www.medimmune.com
MedImmune公司1988年成立于美国马里兰州的Gaithersburg，是一家开发生产抗感染药物，抗肿瘤药物和免疫调节药物的生物技术公司。公司总部位于马里兰州的Gaithersburg，在Frederick，Maryland和荷兰的Ni jmegen有生产厂房，在宾夕凡尼亚州的West Conshohocken有肿瘤学方面的子公司。1999年MedImmune公司兼并了美国Bioscience。公司在纳斯达克的股票代码为MEDI。
2007年英国AstraZeneca公司用156亿美元收购了MedImmune。
   

In the world of biologics, MedImmune has established itself as a true visionary, with one of the most robust pipelines in the biopharmaceutical industry. From groundbreaking research and development, to state-of-the-art manufacturing, to product commercialization, every day we're touching lives. We're proudly united by the spirit of innovation, the heart of inspiration, and the strength of integration, as we advance science for better health.

The value of health. The promise of Biotech. The purpose of MedImmune.

Spirit of Innovation
Renowned for originality and creativity, and backed by a 20-year heritage, MedImmune is synonymous with intelligent risk-taking and accountability. We strive to address unmet medical needs by developing novel proprietary products and cutting-edge technologies. By incorporating translational sciences, otherwise known as "customized medicine," in an increasing number of our clinical programs, MedImmune is continually striving toward the future.

Heart of Inspiration
Today's MedImmune offers a promising future. Our more than 3,000 employees are dedicated to helping people live better lives. We are developing new therapeutic and preventive medicines that hold tremendous potential for patients around the globe in the areas of infectious disease, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. We're committed to making a difference in science, in the lives of patients, and in the communities in which we operate.

Strength of Integration
With locations in the United States, the United Kingdom, and the Netherlands, we all work together toward one goal: helping people live healthier, longer, and more satisfying lives. Established in 2007 as the global biologics business for AstraZeneca, we have continued to advance our R&D portfolio and expand our headcount, research capability, and manufacturing facilities. We are a catalyst for change, forging ahead with a spirit of collective creativity and expertise.